Changing rate of serious infections in biologic-exposed rheumatoid arthritis patients. Data from South American registries BIOBADABRASIL and BIOBADASAR

Incidência de tuberculose em pacientes com artrite reumatoide em uso de bloqueadores do TNF no Brasil: dados do Registro Brasileiro de Monitoração de Terapias Biológicas BiobadaBrasil

(2017) Claudia Leiko Yonekura et al.   Revista Brasileira De Reumatologia

Real-world comparative risks of herpes virus infections in tofacitinib and biologic-treated patients with rheumatoid arthritis

(2016) Jeffrey R Curtis et al.   ANNALS OF THE RHEUMATIC DISEASES

Impact of treatment with biologic DMARDs on the risk of sepsis or mortality after serious infection in patients with rheumatoid arthritis

(2015) A Richter et al.   ANNALS OF THE RHEUMATIC DISEASES

Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL

(2015) Bárbara P. Fafá et al.   CLINICAL RHEUMATOLOGY

A Study of Multiple Causes of Death in Rheumatoid Arthritis

(2015) F. A. G. Pinheiro et al.   JOURNAL OF RHEUMATOLOGY

The Risk of Tuberculosis in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor-  Antagonist: A Metaanalysis of Both Randomized Controlled Trials and Registry/Cohort Studies

(2015) J.-W. Ai et al.   JOURNAL OF RHEUMATOLOGY

Incidence of active mycobacterial infections in Brazilian patients with chronic inflammatory arthritis and negative evaluation for latent tuberculosis infection at baseline - A longitudinal analysis after using TNFa blockers

(2015) Carina Mori Frade Gomes et al.   MEMORIAS DO INSTITUTO OSWALDO CRUZ

The risk of serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors decreased over time: a report from the registry of Japanese rheumatoid arthritis patients on biologics for long-term safety (REAL) database

(2014) Ryoko Sakai et al.   RHEUMATOLOGY INTERNATIONAL

Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0

(2014) Tatiana Cobo-Ibáñez et al.   RHEUMATOLOGY INTERNATIONAL

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis

(2013) Helene Che et al.   JOINT BONE SPINE

Predictors for the 5-year risk of serious infections in patients with rheumatoid arthritis treated with anti-tumour necrosis factor therapy: a cohort study in the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry

(2013) S. A. A. van Dartel et al.   RHEUMATOLOGY

Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?

(2011) A. Strangfeld et al.   ANNALS OF THE RHEUMATIC DISEASES

Incidence and Risk Factors for Serious Infection in Patients with Rheumatoid Arthritis Treated with Tumor Necrosis Factor Inhibitors: A Report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety

(2011) Y. KOMANO et al.   JOURNAL OF RHEUMATOLOGY

Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry

(2011) María José Pérez-Sola et al.   MEDICINA CLINICA

Hanseníase virchowiana associada ao uso de inibidor do fator de necrose tumoral α: relato de caso

(2011) Daniele S Freitas et al.   Revista Brasileira De Reumatologia

Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly

(2010) J. B. Galloway et al.   RHEUMATOLOGY

A Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries

(2010) Jeffrey R. Curtis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Comparison of Anti-TNF Treatment Initiation in Rheumatoid Arthritis Databases Demonstrates Wide Country Variability in Patient Parameters at Initiation of Anti-TNF Therapy

(2010) Chris Pease et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

HLA-DRB1*0901 lowers anti-cyclic citrullinated peptide antibody levels in Japanese patients with rheumatoid arthritis

(2009) Y. Okada et al.   ANNALS OF THE RHEUMATIC DISEASES

The safety of anti-tumour necrosis factor therapy in rheumatoid arthritis

(2009) Johan Askling et al.   CURRENT OPINION IN RHEUMATOLOGY

European biologicals registers: methodology, selected results and perspectives

(2008) A Zink et al.   ANNALS OF THE RHEUMATIC DISEASES